A model-based analysis of the health impacts of COVID-19 disruptions to primary cervical screening by time since last screen for current and future disruptions.
COVID-19
cervical cancer
computational biology
none
simulation modeling
systems biology
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
12 10 2022
12 10 2022
Historique:
received:
08
07
2022
accepted:
15
09
2022
entrez:
12
10
2022
pubmed:
13
10
2022
medline:
15
10
2022
Statut:
epublish
Résumé
We evaluated how temporary disruptions to primary cervical cancer (CC) screening services may differentially impact women due to heterogeneity in their screening history and test modality. We used three CC models to project the short- and long-term health impacts assuming an underlying primary screening frequency (i.e., 1, 3, 5, or 10 yearly) under three alternative COVID-19-related screening disruption scenarios (i.e., 1-, 2-, or 5-year delay) versus no delay in the context of both cytology-based and human papillomavirus (HPV)-based screening. Models projected a relative increase in symptomatically detected cancer cases during a 1-year delay period that was 38% higher (Policy1-Cervix), 80% higher (Harvard), and 170% higher (MISCAN-Cervix) for underscreened women whose last cytology screen was 5 years prior to the disruption period compared with guidelines-compliant women (i.e., last screen 3 years prior to disruption). Over a woman's lifetime, temporary COVID-19-related delays had less impact on lifetime risk of developing CC than screening frequency and test modality; however, CC risks increased disproportionately the longer time had elapsed since a woman's last screen at the time of the disruption. Excess risks for a given delay period were generally lower for HPV-based screeners than for cytology-based screeners. Our independent models predicted that the main drivers of CC risk were screening frequency and screening modality, and the overall impact of disruptions from the pandemic on CC outcomes may be small. However, screening disruptions disproportionately affect underscreened women, underpinning the importance of reaching such women as a critical area of focus, regardless of temporary disruptions.
Identifiants
pubmed: 36222673
doi: 10.7554/eLife.81711
pii: 81711
pmc: PMC9555861
doi:
pii:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : U01 CA253912
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA199334
Pays : United States
Organisme : Cancer Research UK
ID : C8162/A27047
Pays : United Kingdom
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2022, Burger et al.
Déclaration de conflit d'intérêts
EB, Id, JO, MR, EJ, Dd, JK, SH, AC, MR, JK, KC, MS No competing interests declared
Références
J Med Screen. 2021 Jun;28(2):213-216
pubmed: 33730899
J Natl Cancer Inst. 2020 Sep 1;112(9):955-963
pubmed: 31821501
Prev Med. 2021 Dec;153:106826
pubmed: 34599921
Prev Med. 2021 Oct;151:106681
pubmed: 34217422
Int J Cancer. 2020 Aug 1;147(3):887-896
pubmed: 31837006
Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):765-73
pubmed: 24302677
JAMA Netw Open. 2020 Aug 3;3(8):e2017267
pubmed: 32749465
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
Lancet Public Health. 2021 Jul;6(7):e522-e527
pubmed: 33939965
Med Decis Making. 2020 May;40(4):474-482
pubmed: 32486894
Lancet Public Health. 2020 Apr;5(4):e213-e222
pubmed: 32057315
J Natl Cancer Inst. 2011 Mar 2;103(5):368-83
pubmed: 21282563
Prev Med. 2021 Oct;151:106623
pubmed: 34029578
Prev Med. 2018 Apr;109:44-50
pubmed: 29288782
Prev Med. 2022 Jan;154:106871
pubmed: 34762966
JAMA Netw Open. 2021 Apr 1;4(4):e218373
pubmed: 33914050
PLoS Med. 2017 Oct 24;14(10):e1002414
pubmed: 29065127
Prev Med. 2021 Oct;151:106606
pubmed: 34217418
Public Health Rep. 2020 Jul/Aug;135(4):483-491
pubmed: 32516053
J Med Screen. 2022 Sep;29(3):203-208
pubmed: 35369792
BMJ. 2008 Oct 13;337:a1754
pubmed: 18852164
PLoS Med. 2021 Mar 11;18(3):e1003534
pubmed: 33705382
JAMA. 2018 Aug 21;320(7):674-686
pubmed: 30140884